Leukemia & Lymphoma
Specialty Channel

Featured Article
At the Virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.
In a phase 3 study of older patients with AML in remission after chemo, maintenance therapy with CC-486 was tied to significantly longer survival than placebo.
The FDA has approved crizotinib for the treatment of young adults and pediatric patients aged ≥1 year with relapsed or refractory, systemic, ALK-positive ALCL.
True or False: Brentuximab vedotin combined with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas.
Patients with relapsed/refractory DLBCL given AUTO3 (a CD19/22 dual targeting CAR-T therapy) plus pembrolizumab had durable responses.
In a study of patients with relapsed/refractory B-Cell NHL, the ViPOR regimen led to complete responses, with no unexpected toxicities.

News

At the Virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.

Interactive Features

True or False: Brentuximab vedotin combined with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas.
True or False: In the phase 2 ZUMA-2 clinical trial, anti-CD19 CAR-T therapy with KTE-X19 yielded no benefit in the majority of patients with relapsed or refractory MCL.
True or False: Rituximab plus bendamustine administered before autologous SCT in patients with MCL led to very low rates of durable remission in a pooled analysis by Merryman et al.
True or False: Bortezomib maintenance therapy after transplantation yields no positive effect in young patients with MCL.
Stay in the know.
OncNet Newsletter